ArticleInternational journal of nanomedicine2026
Preparation and Evaluation of Docetaxel-Loaded Targeted Poly (β‑amino Ester) - Magnetic Nanoparticles for Chemo‑Magnetodynamic Therapy Under Low‑Frequency Magnetic Fields.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Magnetodynamic therapy (MDT), which utilizes the mechanical motion of magnetic nanoparticles (MNPs) under low-frequency magnetic fields (LFMFs), has emerged as a promising approach to overcome the major limitations of traditional chemotherapy. This study aims to evaluate an integrated therapeutic strategy, termed chemo-MDT, under in vitro conditions. Methods: In this study, MNPs were modified with poly (β-amino ester) (PBAE) and functionalized with a CD44 aptamer for targeted delivery of docetaxel (DTX). The drug loading efficiency (LE) and drug loading capacity (LC) were determined. We investigated the effects of various LFMFs, specifically alternating magnetic fields (LFAMF), static magnetic fields (LFSMF), and their combination (LFSAMF), on the physicochemical properties, drug release, cellular uptake, and viability of 4T1 cancer cells. Results: The LE and LC of the engineered nanoparticles were found to be 91.92% and 8.35%, respectively. Aptamer-mediated targeting increased cellular uptake by 1.4-fold and enhanced magnetodynamic therapeutic efficiency by approximately two-fold compared to non-targeted nanoparticles. At the IC25 dose, DTX-loaded nanoparticles (NDTX) reduced cell viability to 71%, while the CD44 aptamer-functionalized ones (apt-NDTX) decreased it to 49.77%. Subsequent exposure to LFAMF led to a further reduction in viability to 36.75%. This improvement is primarily attributed to the intrinsic magnetodynamic effect arising from nanoparticle oscillation and the disruption of CD44-associated membrane protein complexes, rather than changes in drug release or uptake, both of which remained unaffected by LFAMF. Conversely, static magnetic fields produced negligible and, in some cases, slightly adverse effects on physicochemical or therapeutic properties; however, the combination of alternating and static fields mitigated these adverse effects. Conclusion: Collectively, these findings demonstrate that targeted delivery, when combined with magnetodynamic stimulation, forms an effective integrated chemo-MDT strategy that significantly enhances cancer cell killing through complementary targeting and mechanical mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.